The quantified TACS information completed the patient-specific quantification in this study that also included age, molecular subtype (Luminal A, Luminal B, HER2-enriched, or Triple-negative), tumor size, nodal status, histological grade, clinical stage, (chemo-, endocrine, radiation, and/or targeted) therapy, and DFS (Tables S2-S3). Here, ERBB2 is linked to neoplasm.